

Cont
A9

28. Acid addition salts according to Claim 13, wherein a nitroxyl group is present at N₁₇.

29. Acid addition salts according to Claim 13, wherein the alcohol of the monoester is methanol.

30. Acid addition salts according to Claim 13, wherein the carboxyl group function of the 5-ring or 6-ring heterocycles is selected from carboxy, carboxymethyl and carboxyethyl. -

IN THE ABSTRACT:

Delete the original Abstract and substitute therefor the Abstract appended hereto on a separate page.



ABSTRACT OF THE DISCLOSURE

A 10

A transdermal or transmucosal composition for administering morphine alkaloids in form of an acid addition salt of a morphine alkaloid and an organic acid is provided, wherein the organic acid is selected from: monoesters of C_3 - to C_{16} -dicarboxylic acids with monohydric C_1 - to C_4 -alcohols; C_2 - to C_6 - or C_8 - to C_{16} -sulfonic acids; substituted benzoic acids, selected from the group of halogen, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl and/or alkoxy-substituted benzoic acid, and aminosubstituted benzoic acids, which may optionally be alkylated at the N atom; substituted or unsubstituted 5-ring or 6-ring heterocycles comprising at least one N or S atom and having a carboxyl group function; saturated or unsaturated, optionally substituted, oxocarboxylic acids having 5 to 10 C atoms; phenyl-substituted or phenoxy-substituted saturated C_2 - to C_4 -carboxylic acids; and aliphatic, aromatic or heterocyclic C_2 - to C_{12} -amino acids, wherein one amino group is substituted with a substituted or unsubstituted C_2 - to C_6 -alkanoyl group or a substituted or unsubstituted benzoyl group.
